PRVB News and Press, Provention Bio Inc. From 11/03/22

Provention Bio press release ( NASDAQ: PRVB ): Q3 GAAP EPS of -$0.34 beats by $0.08 . Revenue of $0.8M (+17.6% Y/Y) beats by $0.02M . Cash-based operating expenses for the third quarter of 2022 were $26.4M, which exclude non-cash, stock-based compensation expen...

Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update PR Newswire Continues to Advance Preparations for Potential U.S. Commercial Launch of Teplizumab Ahead of November 17 th FDA User Fee Goal Date RED BANK, N.J....

Summary Provention Bio's lead candidate is in limbo with its extended PDUFA. Its Sanofi deal is multifaceted, but a reliable lifeline it is not. The company's investment prospects are dicey at best. This is my first look at Provention Bio ( PRVB ), another biotec...

Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022 PR Newswire RED BANK, N.J. , Oct. 13, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-m...

Fortunes can change quickly in the volatile biotech industry. And few things can impact drugmakers' performance -- and prospects -- the way regulatory approvals can. That's why it's a good idea for biotech investors to keep an eye on upcoming regulatory decisions. With that as a backdro...

Provention Bio ( NASDAQ: PRVB ) said it will get $20M upfront from Sanofi ( NASDAQ: SNY ) in exchange for granting the French pharma giant an exclusive right of first negotiation to license teplizumab globally for type 1 diabetes. In addition, Provention entered ...

The stock market continued to try to build a base on Thursday after a punishing first nine months of 2022. Two days of big gains on Monday and Tuesday set the stage for a nice recovery, and Wednesday's recovery from steep losses showed the market's resilience. Futures markets for the Dow ...

Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals PR Newswire Provention receives $20 million nonrefundable payment granting Sanofi exclusive rig...

Things can change quickly in the volatile biotech industry. Just ask Provention Bio (NASDAQ: PRVB) . The autoimmune disease-focused drugmaker seemed on the verge of earning a major regulatory approval for its leading candidate, teplizumab, in early 2021. However, because of regulato...

Provention Bio ( NASDAQ: PRVB ) has announced that the Co. has appointed Sarah O'Brien as Chief People Officer. "Sarah joins us at a key juncture, as we work to scale and grow Provention Bio while staying relentlessly focused on our purpose to intercept and prevent life-th...